Drug Information

Drug General Information
Drug ID
D0YI5E
Former ID
DNCL003354
Drug Name
Bydureon Dual Chamber Pen
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Approved [550291]
Company
AstraZeneca
Target and Pathway
Target(s) Glucagon-like peptide 1 receptor Target Info Modulator [532841]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Reactome Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 550291US FDA approves Bydureon? Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes
Ref 532841Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.